Patents by Inventor Tsukasa Ishihara
Tsukasa Ishihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11542523Abstract: An object of the present invention is to provide an animal cell with improved proliferation ability and survival rate, a method for producing the animal cell, and a method for producing a target protein formed of the animal cell. According to the present invention, there is provided an animal cell having a gene encoding a target protein and a foreign gene encoding an isovaleryl-CoA dehydrogenase, in which the isovaleryl-CoA dehydrogenase is overexpressed.Type: GrantFiled: June 10, 2020Date of Patent: January 3, 2023Assignee: FUJIFILM CorporationInventors: Tatsuya Matsuura, Tsukasa Ishihara
-
Publication number: 20220290204Abstract: An object of the present invention is to provide a cell culture method having an excellent cell proliferation property, an antibody production method using the above method, an organic acid removal method using the above method, and an antibody produced by the above method. The cell culture method of the present invention is a cell culture method including a metabolic decomposition product removal step of bringing a culture solution containing a metabolic decomposition product into contact with a polymer having a quaternary ammonium base group or an amino group and removing the metabolic decomposition product from the culture solution to a purified culture solution and a cell culture step of culturing cells using the purified culture solution.Type: ApplicationFiled: May 27, 2022Publication date: September 15, 2022Applicant: FUJIFILM CorporationInventors: Katsuhiro SHIMONO, Yoshinobu HIRAI, Tsukasa ISHIHARA
-
Publication number: 20210147781Abstract: Provide are a cell culture method which includes using a culture vessel which contains a cell suspension containing cells and discharging a gas including 30% by volume or more of oxygen into the cell suspension from a sparger disposed in the culture vessel to culture the cells, in which an average hole diameter in a gas discharge portion in the sparger is 1 ?m or more and 300 ?m or less, and a surface area A (m2) in the gas discharge portion in the sparger, a volume X (m3) of the cell suspension in the culture vessel, and a flow rate Q (m3/min) of the gas that is discharged from the sparger satisfy a specific relationship, a product producing method including the cell culture method, and a cell culture device that enables the cell culture method.Type: ApplicationFiled: November 25, 2020Publication date: May 20, 2021Applicant: FUJIFILM CorporationInventors: Shinichi NAKAI, Kosuke TANIGUCHI, Nobuyuki HARAGUCHI, Tsukasa ISHIHARA
-
Publication number: 20200299723Abstract: An object of the present invention is to provide an animal cell with improved proliferation ability and survival rate, a method for producing the animal cell, and a method for producing a target protein formed of the animal cell. According to the present invention, there is provided an animal cell having a gene encoding a target protein and a foreign gene encoding an isovaleryl-CoA dehydrogenase, in which the isovaleryl-CoA dehydrogenase is overexpressed.Type: ApplicationFiled: June 10, 2020Publication date: September 24, 2020Applicant: FUJIFILM CorporationInventors: Tatsuya MATSUURA, Tsukasa ISHIHARA
-
Patent number: 10532048Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: GrantFiled: July 5, 2018Date of Patent: January 14, 2020Assignee: Seldar Pharma Inc.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Publication number: 20190000832Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: ApplicationFiled: July 5, 2018Publication date: January 3, 2019Applicant: Selder Pharma Inc.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Patent number: 10016410Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: GrantFiled: November 14, 2016Date of Patent: July 10, 2018Assignee: Seldar Pharma Inc.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Publication number: 20170189390Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: ApplicationFiled: November 14, 2016Publication date: July 6, 2017Applicant: Seldar Pharma Inc.Inventors: Hiroyuki Hisamichi, ltsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Patent number: 9526719Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: GrantFiled: August 26, 2015Date of Patent: December 27, 2016Assignee: Seldar Pharma Inc.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Patent number: 9399038Abstract: A method for preventing or treating a disease selected from the group consisting of visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia in a subject in need thereof, comprising administering to said subject an effective amount of the compound of the following formula (I) or a salt thereof: wherein R1, R2, R3, R4, R5, X and n are as described herein.Type: GrantFiled: January 23, 2015Date of Patent: July 26, 2016Assignee: Astellas Pharma Inc.Inventors: Tsukasa Ishihara, Kazuhiro Ikegai, Ikumi Kuriwaki, Hiroyuki Hisamichi, Nobuaki Takeshita, Ryuichi Takezawa
-
Publication number: 20150359787Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: ApplicationFiled: August 26, 2015Publication date: December 17, 2015Applicant: Seldar Pharma Inc.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Patent number: 9150541Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: GrantFiled: July 15, 2013Date of Patent: October 6, 2015Assignee: Seldar Pharma Inc.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Publication number: 20150133433Abstract: A method for preventing or treating a disease selected from the group consisting of visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia in a subject in need thereof, comprising administering to said subject an effective amount of the compound of the following formula (I) or a salt thereof: wherein R1, R2, R3, R4, R5, X and n are as described herein.Type: ApplicationFiled: January 23, 2015Publication date: May 14, 2015Applicant: ASTELLAS PHARMA INC.Inventors: Tsukasa ISHIHARA, Kazuhiro IKEGAI, Ikumi KURIWAKI, Hiroyuki HISAMICHI, Nobuaki TAKESHITA, Ryuichi TAKEZAWA
-
Patent number: 8981119Abstract: The present invention is directed to compounds of Formula I: wherein R1, R2, R3, R4, R5, X and n are described herein. These compounds and their pharmaceutically acceptable salts thereof are useful as IK1 channel activators.Type: GrantFiled: June 6, 2014Date of Patent: March 17, 2015Assignee: Astellas Pharma Inc.Inventors: Tsukasa Ishihara, Kazuhiro Ikegai, Ikumi Kuriwaki, Hiroyuki Hisamichi, Nobuaki Takeshita, Ryuichi Takezawa
-
Publication number: 20140364421Abstract: [Problem] A compound which is useful as an IK1 channel activator is provided. [Means for Solution] As a result of studies on the IK1 channel activator, the present inventors have found that a benzothiophene compound shows effectiveness on visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, or fibromyalgia, thereby completing the invention. A compound of the invention has an IK1 channel activation effect, and can also be used as an agent for preventing and/or treating visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, or fibromyalgia. In addition, the IK1 channel activator can be used as an agent for preventing and/or treating inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia.Type: ApplicationFiled: June 6, 2014Publication date: December 11, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Tsukasa ISHIHARA, Kazuhiro IKEGAI, Ikumi KURIWAKI, Hiroyuki HISAMICHI, Nobuaki TAKESHITA, Ryuichi TAKEZAWA
-
Publication number: 20140058100Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: ApplicationFiled: July 15, 2013Publication date: February 27, 2014Applicant: Seldar Pharma Inc.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Patent number: 8518490Abstract: In a coating zone, a cylindrical tube is soaked in and taken out from a solution, such that a coating film is formed on a curved surface of the tube. In a wet gas zone, while a first gas feeding nozzle having a gas outlet moves in a state where the gas outlet faces an outer peripheral surface of the tube, wet gas is blown toward the coating film through the gas outlet. Water drops are generated on the coating film and grown up. In a dry gas zone, as in the case of the first gas feeding nozzle, while a second gas feeding nozzle having a gas outlet moves, dry gas is blown toward the coating film through the gas outlet. Solvent and water drops are evaporated from the coating film. Pores form from the water drops as a template for the porous material on the coating film.Type: GrantFiled: March 30, 2010Date of Patent: August 27, 2013Assignee: Fujifilm CorporationInventors: Koju Ito, Tsukasa Ishihara, Hidekazu Yamazaki
-
Patent number: 8486970Abstract: [Problems] To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). [Means for Solving Problems] It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: GrantFiled: May 26, 2008Date of Patent: July 16, 2013Assignee: Seldar Pharma Inc.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Patent number: 8187852Abstract: A porous film is used as a cell culture substrate that is a scaffold for a spheroid. The porous film has a plurality of pores whose diameters gradually increase in a direction A. The diameters of the pores gradually increase from a first area P1 to a third area P3 in this order. The first to the third areas P1 to P3 are located on the porous film along the direction A. The diameters and depths of the pores increase in proportion to the distance in the direction A.Type: GrantFiled: March 26, 2009Date of Patent: May 29, 2012Assignee: FUJIFILM CorporationInventors: Hidekazu Yamazaki, Tsukasa Ishihara
-
Patent number: RE43481Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4?-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.Type: GrantFiled: September 3, 2008Date of Patent: June 19, 2012Assignee: Astellas Pharma Inc.Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Hachiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi Shigenaga, Souichirou Kawazoe